2024 JUNE

Transporters and liver disease
Drug Metab Dispos. 2024;52:355-367. Pharmacokinetic effects of different models of Nonalcoholic Fatty Liver Disease in transgenic humanized OATP1B mice. Bechtold BJ, Lynch KD, Oyanna VO, Call MR, White LA, Graf TN, Oberlies NH, Clarke JD. PubMed

Transporters and DDI
Mol Pharm. 2024;In press. Rifampin- and Silymarin-mediated pharmacokinetic interactions of exogenous and endogenous substrates in a transgenic OATP1B mouse model. Bechtold BJ, Lynch KD, Oyanna VO, Call MR, Graf TN, Oberlies NH, Clarke JD. PubMed

Clin Pharmacol Ther. 2024;In press. Comprehensive evaluation of OATP- and BCRP-mediated drug-drug interactions of Methotrexate using Physiologically-Based Pharmacokinetic Modeling. Hwang S, Lee Y, Jang Y, Cho JY, Yoon S, Chung JY. PubMed

Toxicol In Vitro. 2024;In press. Interactions of oleanane pentacyclic triterpenoids with human organic anion transporting polypeptide 1B1 and 1B3. Tian Y, Wang X, Bi Y, Li X, Zhang Y, Yao Y, Zhang M, Xu T, Zhang Y, Gui C, Zhang W, Zhang C, Yu H, Zhang Y. PubMed

Experimental models

Eur J Pharm Sci. 2024;196:106760. Ex vivo gut-hepato-biliary organ perfusion model to characterize oral absorption, gut-wall metabolism, pre-systemic hepatic metabolism and biliary excretion; application to midazolam. Stevens LJ, van de Steeg E, Doppenberg JB, Alwayn IPJ, Knibbe CAJ, Dubbeld J. PubMed

Drug Metab Dispos. 2024;52:539-547. Comparison of human long-term liver models for clearance prediction of slowly metabolized compounds. Preiss LC, Georgi K, Lauschke VM, Petersson C. PubMed

Drug Metab Dispos. 2024;52:345-354. Improving in vitro-in vivo extrapolation of clearance using rat liver microsomes for highly plasma protein-bound molecules. Trunzer M, Teigão J, Huth F, Poller B, Desrayaud S, Rodríguez-Pérez R, Faller B. PubMed

Am J Physiol Gastrointest Liver Physiol. 2024;In press. Assessing the degree of hepatic ischemia-reperfusion injury using PBPK modeling of sodium fluorescein disposition in ex vivo machine-perfused livers. Monti CE, Hong SK, Audi SH, Lee W, Joshi A, Terhune SS, Kim J, Dash RK. PubMed

Drug Metab Dispos. 2024;In press. Evaluation and optimization of a microcavity plate-based human hepatocyte spheroid model for predicting clearance of slowly metabolized drug candidates. Kukla DA, Belair DG, Stresser DM. PubMed

Arch Toxicol. 2024;In press. Formation of functional, extended bile canaliculi, and increased bile acid production in sandwich-cultured human cryopreserved hepatocytes using commercially available culture medium. Horiuchi S, Kuroda Y, Oyafuso R, Komizu Y, Maeda K, Ishida S. PubMed

Toxicology. 2024;In press. A 3D spheroid model of quadruple cell co-culture with improved liver functions for hepatotoxicity prediction. Sun B, Liang Z, Wang Y, Yu Y, Zhou X, Geng X, Li B. PubMed

Transporters and translation to humans
Clin Pharmacol Ther. 2024;In press. Sex and the kidney drug-metabolizing enzymes and transporters: Are preclinical drug disposition data translatable to humans? Thakur A, Yue G, Ahire D, Mettu VS, Al Maghribi A, Ford K, Peixoto L, Leeder JS, Prasad B. PubMed

Transporters and hepatic clearance
Drug Metab Dispos. 2024;52:548-554. Using the dynamic well-stirred model to extrapolate hepatic clearance of Organic Anion-Transporting Polypeptide transporter substrates without assuming albumin-mediated hepatic drug uptake.Yan Z, Ma L, Hwang N, Huang J, Kenny JR, Hop CECA. PubMed

Drug Metab Dispos. 2024;52:390-398 In vitro to in vivo scalars for drug clearance in Nonalcoholic Fatty Liver and Steatohepatitis. Sierra T, Achour B. PubMed

Transporters and drug development
Drug Metab Dispos. 2024;52:582-596. Survey of pharmaceutical industry's best practices around in vitro transporter assessment and implications for drug development: Considerations from the international consortium for innovation and Quality for pharmaceutical development transporter working group. Rollison HE, Mitra P, Chanteux  H, Fang ZZ, Liang X, Park SH, Costales C, Hanna I, Thakkar N, Vergis JM, Bow  DAJ, Hillgren KM, Brumm J, Chu  X, Hop CECA, Lai Y, Li CY, Mahar KM, Salphati  L, Sane  R, Shen H, Taskar K, Taub M, Tohyama  K, Xu C, Fenner KS. PubMed

Transporters and structure
Biophys J. 2024;In press. Coupling the role of lipids to the conformational dynamics of the ABC transporter P-glycoprotein. De Vecchis D, Schäfer LV. PubMed

Transporters and zonal distribution
CPT Pharmacometrics Syst Pharmacol. 2024;In press. Hepatic OATP1B zonal distribution: Implications for rifampicin-mediated drug-drug interactions explored within a PBPK framework. Hartauer M, Murphy WA, Brouwer KLR, Southall R, Neuhoff S. PubMed

Transporters and endocytosis
Life Sci. 2024;In press.Tauroursodeoxycholate prevents estradiol 17beta-d-glucuronide-induced cholestasis and endocytosis of canalicular transporters by switching off pro-cholestatic signaling pathways. Medeot AC, Boaglio AC, Salas G, Maidagan PM, Miszczuk GS, Barosso IR, Sánchez Pozzi EJ, Crocenzi FA, Roma MG. PubMed

Transporters and endoplasmic reticulum
Biochem Pharmacol. 2024;225:116322. Endoplasmic reticulum transporter OAT2 regulates drug metabolism and interaction. Arakawa H, Ishida N, Nakatsuji T, Matsumoto N, Imamura R, Shengyu D, Araya K, Horike SI, Tanaka-Yachi R, Kasahara M, Yoshioka T, Sumida Y, Ohmiya H, Daikoku T, Wakayama T, Nakamura K, Fujita KI, Kato Y. PubMed

Transporter and machine learning
Pharmaceutics. 2024;16:592. Distinguishing molecular properties of OAT, OATP, and MRP drug substrates by machine learning. Nigam AK, Momper JD, Ojha AA, Nigam SK. PubMed

Transporters and pharmacokinetic modelling
CPT Pharmacometrics Syst Pharmacol. 2024; In press. Elucidating nonlinear pharmacokinetics of telmisartan: Integration of target-mediated drug disposition and OATP1B3-mediated hepatic uptake in a physiologically based model. Tsuchitani T, Tomaru A, Aoki Y, Ishiguro N, Tsuda Y, Sugiyama PubMed

Reviews
Toxicol Sci. 2024;In press. Effects of PFAS on human liver transporters: implications for health outcomes. Vujic E, Ferguson SS, Brouwer KLR. PubMed